File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome

TitleProspective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome
Authors
KeywordsMembranous nephropathy
Mycophenolate mofetil
Nephrotic syndrome
Issue Date2007
PublisherBlackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/NEP
Citation
Nephrology, 2007, v. 12 n. 6, p. 576-581 How to Cite?
AbstractBackground: Retrospective and anecdotal data suggest that mycophenolate mofetil (MMF) might be effective when given as rescue therapy for membranous nephropathy (MN). Prospective controlled data on MMF and prednisolone as primary therapy are lacking. Methods: A prospective, randomized, controlled, open-label study was performed to investigate the efficacy and tolerability of MMF and prednisolone as primary treatment in MN with nephrotic syndrome. MMF and prednisolone given for 6 months was compared against a modified Ponticelli regimen in 20 patients, with follow up of 15 months. Results: MMF with prednisolone and the comparative immunosuppressive regimen showed similar efficacy in proteinuria reduction, despite a lower cumulative prednisolone dose in the MMF group (3.80 ± 0.28 vs 9.93 ± 0.25 g, P < 0.001). Remission (composite of 'complete' and 'partial') rates were 63.6% and 66.7% in the MMF group and control group, respectively (P = 1.000). Serum creatinine and creatinine clearance remained stable during follow up. Cumulative relapse rate was 23.1% at 2 years. Chlorambucil resulted in more leucopenia compared with MMF. Conclusion: Data from this pilot study indicate that more than 60% of patients with MN and nephrotic syndrome respond to combined MMF and prednisolone treatment, and suggest potential benefits of MMF as being steroid-sparing and having less adverse effects compared with other commonly used cytotoxic agents. © 2007 The Authors.
Persistent Identifierhttp://hdl.handle.net/10722/78389
ISSN
2015 Impact Factor: 1.796
2015 SCImago Journal Rankings: 0.894
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChan, TMen_HK
dc.contributor.authorLin, AWen_HK
dc.contributor.authorTang, SCWen_HK
dc.contributor.authorQian, JQen_HK
dc.contributor.authorLam, MFen_HK
dc.contributor.authorHo, YWen_HK
dc.contributor.authorTse, KCen_HK
dc.contributor.authorChan, KWen_HK
dc.contributor.authorLai, KNen_HK
dc.contributor.authorTang, CSen_HK
dc.date.accessioned2010-09-06T07:42:20Z-
dc.date.available2010-09-06T07:42:20Z-
dc.date.issued2007en_HK
dc.identifier.citationNephrology, 2007, v. 12 n. 6, p. 576-581en_HK
dc.identifier.issn1320-5358en_HK
dc.identifier.urihttp://hdl.handle.net/10722/78389-
dc.description.abstractBackground: Retrospective and anecdotal data suggest that mycophenolate mofetil (MMF) might be effective when given as rescue therapy for membranous nephropathy (MN). Prospective controlled data on MMF and prednisolone as primary therapy are lacking. Methods: A prospective, randomized, controlled, open-label study was performed to investigate the efficacy and tolerability of MMF and prednisolone as primary treatment in MN with nephrotic syndrome. MMF and prednisolone given for 6 months was compared against a modified Ponticelli regimen in 20 patients, with follow up of 15 months. Results: MMF with prednisolone and the comparative immunosuppressive regimen showed similar efficacy in proteinuria reduction, despite a lower cumulative prednisolone dose in the MMF group (3.80 ± 0.28 vs 9.93 ± 0.25 g, P < 0.001). Remission (composite of 'complete' and 'partial') rates were 63.6% and 66.7% in the MMF group and control group, respectively (P = 1.000). Serum creatinine and creatinine clearance remained stable during follow up. Cumulative relapse rate was 23.1% at 2 years. Chlorambucil resulted in more leucopenia compared with MMF. Conclusion: Data from this pilot study indicate that more than 60% of patients with MN and nephrotic syndrome respond to combined MMF and prednisolone treatment, and suggest potential benefits of MMF as being steroid-sparing and having less adverse effects compared with other commonly used cytotoxic agents. © 2007 The Authors.en_HK
dc.languageengen_HK
dc.publisherBlackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/NEPen_HK
dc.relation.ispartofNephrologyen_HK
dc.subjectMembranous nephropathyen_HK
dc.subjectMycophenolate mofetilen_HK
dc.subjectNephrotic syndromeen_HK
dc.subject.meshAdolescenten_HK
dc.subject.meshAdulten_HK
dc.subject.meshAgeden_HK
dc.subject.meshFemaleen_HK
dc.subject.meshGlomerulonephritis, Membranous - drug therapyen_HK
dc.subject.meshHumansen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshMycophenolic Acid - adverse effects - analogs & derivatives - therapeutic useen_HK
dc.subject.meshNephrotic Syndrome - drug therapyen_HK
dc.subject.meshPrednisolone - adverse effects - therapeutic useen_HK
dc.subject.meshTreatment Outcomeen_HK
dc.titleProspective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndromeen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1320-5358&volume=12&spage=576&epage=581&date=2007&atitle=Prospective+controlled+study+on+mycophenolate+mofetil+and+prednisolone+in+the+treatment+of+membranous+nephropathy+with+nephrotic+syndromeen_HK
dc.identifier.emailChan, TM: dtmchan@hku.hken_HK
dc.identifier.emailTang, SCW: scwtang@hku.hken_HK
dc.identifier.emailChan, KW: hrmtckw@hku.hken_HK
dc.identifier.emailLai, KN: knlai@hku.hken_HK
dc.identifier.authorityChan, TM=rp00394en_HK
dc.identifier.authorityTang, SCW=rp00480en_HK
dc.identifier.authorityChan, KW=rp00330en_HK
dc.identifier.authorityLai, KN=rp00324en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1440-1797.2007.00822.xen_HK
dc.identifier.pmid17995584-
dc.identifier.scopuseid_2-s2.0-35848969105en_HK
dc.identifier.hkuros139118en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-35848969105&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume12en_HK
dc.identifier.issue6en_HK
dc.identifier.spage576en_HK
dc.identifier.epage581en_HK
dc.identifier.isiWOS:000250819400008-
dc.publisher.placeAustraliaen_HK
dc.identifier.scopusauthoridChan, TM=7402687700en_HK
dc.identifier.scopusauthoridLin, AW=7402060898en_HK
dc.identifier.scopusauthoridTang, SCW=7403437082en_HK
dc.identifier.scopusauthoridQian, JQ=7402195779en_HK
dc.identifier.scopusauthoridLam, MF=35300050600en_HK
dc.identifier.scopusauthoridHo, YW=7402555047en_HK
dc.identifier.scopusauthoridTse, KC=7102609864en_HK
dc.identifier.scopusauthoridChan, KW=16444133100en_HK
dc.identifier.scopusauthoridLai, KN=7402135706en_HK
dc.identifier.scopusauthoridTang, CS=8681865300en_HK
dc.identifier.citeulike1872791-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats